Hematologic cell-line sensitivity screen
Cell-based study · Panel of 15 hematologic cancer cell lines; Figure 1A displays 13, with TK and B104 DLBCL results described in Results. [1]
Responses varied substantially. Mantle-cell, Burkitt lymphoma and T-ALL models included responsive lines, whereas myeloma and AML models showed relatively weak responses. Granta519 and NCEB-1 were described as highly resistant. These are growth-inhibition endpoints rather than direct binding potency.
| Endpoint | Reported result | Reference |
|---|---|---|
| Cell proliferation relative to untreated cells | 72-hour MTT growth inhibition Variable response; relatively weak activity in myeloma/AML models; Granta519 and NCEB-1 highly resistant. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Various concentrations; no exact dose series transcribed from plotted bars.
- Exposure duration
- 72 hours
- Method
- Cell proliferation measured by tetrazolium reduction, expressed relative to corresponding untreated cells.
- Co-treatment
- Single-agent sensitivity screen.
- Reported limits
- Vehicle and complete concentration series are not specified in the read screen description. No individual IC50 or IC80 values were estimated from bar heights.
Methods and source locations
Compound reported in the paper: Bendamustine hydrochloride; Compound label in the paper: BDM
Evidence concerns the reported SymBio material; no equivalence of formulation or validation of an Adooq lot is established.
Figure 1A and caption; Materials and Methods: Drugs, Cell Lines, Cell Proliferation Assay; first Results subsection
Cell proliferation relative to untreated cells: MTT reduction assay; untreated cells define the reference. Figure 1A reports mean ± SD of three independent experiments. Individual bar heights were not digitized. — Figure 1A and caption; Results: Bendamustine Induces Apoptosis Faster than other Alkylating Agents but does not Exert Sufficient Cytotoxicity against all Tumors